Risk factors for the involvement of sentinel lymph nodes in endometrial cancer (TRSGO-SLN-010)
- 31 December 2024
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (1) , 100041
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- FIGO staging of endometrial cancer: 2023International Journal of Gynecology & Obstetrics, 2023
- Success Rates of Sentinel Lymph Node Mapping for Endometrial Cancer in Patients with Body Mass Index < 45 Compared with Body Mass Index ≥ 45Journal of Minimally Invasive Gynecology, 2023
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysisGynecologic Oncology, 2019
- Risk factors for failure of sentinel lymph node mapping using indocyanine green/near-infrared fluorescent imaging in endometrial cancerArchives of Gynecology and Obstetrics, 2019
- Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessmentGynecologic Oncology, 2018
- Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysisAmerican Journal of Obstetrics and Gynecology, 2017
- Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?Journal of Minimally Invasive Gynecology, 2016
- The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: Beyond removal of blue nodesGynecologic Oncology, 2012
- Revised FIGO staging for carcinoma of the vulva, cervix, and endometriumInternational Journal of Gynecology & Obstetrics, 2009